Clinical Trial Search

Primary: PK Outcome: Geometric Mean Area Under the Plasma Concentration-time Curve (AUC) of Remdesivir (RDV) in Arm 1 — 1246.57 h*ng/mL

Primary: Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion — 191; 171 nmol/min per 300 min — p=0.02

Primary: Number of Subjects With Objective Response Rate (ORR) in EEC or EOC Patients — 2; 0; 0; 0 participants

Primary: Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores — 0.76; 2.15 score on a scale — p=0.0456

Primary: Neoadjuvant Rectal Cancer (NAR) Score — 12.6; 13.7; 14.1; 11.5 score on a scale — p=0.69

Primary: Adequacy of Oral Intake of Energy — 41; 36 kcal/kg/d

Primary: Median Cmax of Naltrexone (After 1st Dose) — 14.10 ng/mL

Primary: Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of Nivolumab as Maintenance Therapy — 33 Participants

Primary: Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the…

Primary: Smoking Status at 3-month Follow Up — .57; .39 proportion abstinent — p==.014

Primary: Visual Acuity - Continuous — -5.5 Letter seen on eye chart

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Obsessive Compulsive Symptoms as Measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) — 23.9; 23.1; 23.23; 20.6 score on a scale

Primary: Midazolam Area Under the Concentration vs. Time Curve (AUC) — 58.3; 80.8 nM * hr

Primary: Walking Physical Activity as Measured by Change in Daily Steps From Baseline to 14 Weeks — -229.52; 1570.17 steps